| INTRODUC TI ON
Ischemic preconditioning (IPC) is a cardioprotective strategy in which brief episodes of ischemia and reperfusion protect the heart from subsequent prolonged ischemia. 1, 2 The concept of IPC was expanded to remote preconditioning in which repeated cycles of nonlethal ischemia and reperfusion to distant tissue provide protection to heart against sustained ischemic injury. 3 Moreover, pharmacological agents are also effective in inducing preconditioning-like effects and this phenomenon is referred to as pharmacological preconditioning.
Different agents that are reported to produce pharmacological preconditioning include adenosine, nitric oxide, thrombin, bradykinin, opioids, statins, some volatile anesthetics, and K ATP channel openers, etc. 4, 5 Adenosine is a naturally occurring endogenous purine nucleoside that modulates physiological functions such as blood flow, heart rate, contractility, and vasodilation. 6 Four types of adenosine receptors, A 1, A 2 A , A 2 B, A 3 , have been identified and these belong to the family of G protein-coupled receptors. A 1 and A 3 are G i-coupled
receptors that inhibit adenylyl cyclase activity and cAMP production; whereas, A 2 A and A 2 B receptors are G s -coupled receptors that activate adenylyl cyclase and cAMP production. Adenosine receptors are widely distributed in body, including heart and coronary smooth muscle and endothelial cells of the aorta. 7 Adenosine agonists have been shown to reduce myocardial ischemia-reperfusioninduced injury. Furthermore, adenosine is a key mediator of ischemic preconditioning that activates a cascade of cardioprotective pathways to protect myocardium from sustained ischemia-reperfusion injury. 8, 9 However, the precise mechanisms involved in adenosine preconditioning-induced cardioprotection are not clear.
Endothelium is a dynamic tissue and it responds quickly to any change in blood flow and hypoxia by releasing different humoral factors including nitric oxide (NO). It is produced from amino acid L-arginine by the enzymatic action of nitric oxide synthase (NOS).
Nitric oxide is a key endogenous mediator that protects heart from ischemic injury 10 and it is documented that nitric oxide acts as a trigger during ischemic preconditioning. 11 Leukotrienes (LTs) are the biologically active molecules of eicosanoid family, and these are synthesized in response to immunological stimuli. 12 These are synthesized by leukocytes via activation of enzyme 5-lipoxygenase, 13 and the major leukotrienes include LTC 
| Animals, drugs, and chemicals
Wistar albino rats (180-250 g) were fed on standard laboratory
Chow (Ashirwad Industries, Mohali, India) and had free access to water and food. In this study, adenosine (Samarth Life Sciences Pvt.
Ltd., India), sodium nitroprusside, as nitric oxide donor (Samarth Life Sciences Pvt. Ltd., India), L-NAME, as NOS inhibitor (Cayman 
| Isolated rat heart preparation
Rats were anesthetized using thiopentone sodium (50 mg/kg ip), and all pharmacological interventions were given in anesthetized conditions. Heparin (500 IU/kg, ip) was administered about 20 minutes before sacrificing rats by cervical dislocation, and heart was immediately mounted on Langendorff's apparatus using a cannula. The heart was perfused with Krebs-Henseleit (KH) solution at a perfusion pressure of 70 mm Hg, pH 7.4, temperature 37°C and mixed with 95% O 2 and 5% CO 2 . The perfusion pressure was kept constant at 70 mm of Hg, and the flow rate at this perfusion pressure was in the range of 7-8 mL/min. A latex balloon filled with fluid was inserted into the left ventricle of perfused heart to measure left ventricular developed pressure (LVDP), maximum rate of contraction (dp/dt max ), and the maximum rate of relaxation (dp/dt min ) with Lab chart software (AD instruments, Australia 
| Infarct size measurement
After 120 minutes of reperfusion, the heart was detached from
Langerdorff apparatus and stained with 1% TTC (triphenyl tetrazolium chloride).The infarct size was determined using volume and weight method.
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| Estimation of lactate dehydrogenase (LDH)
After mounting the heart on the Langendorff apparatus, the coronary effluent samples were collected (in a china dish) at different time intervals, that is, immediately before ischemia (basal), immediately after reperfusion, and 30 minutes after reperfusion. These coronary effluent samples were analyzed to measure LDH levels using 2,4-dinitrophenylhydrazine (2,4-DNPH) method. 
| Estimation of creatine kinase (CK)
During the heart perfusion and reperfusion with the KH solution on the Langendorff apparatus, the coronary effluent samples were collected immediately before ischemia (basal) and 5 minutes after reperfusion. These samples were analyzed to measure CK release from heart using creatine phosphokinase kit. 
| Estimation of serum nitrite
After 40 minutes of adenosine (adenosine preconditioning) or SNP administration (SNP preconditioning) as described in group II and group III of experimental protocol section, the blood was isolated from rat, and serum was separated. Thereafter, serum was employed to measure the nitrite levels by Griess method. 29 
| Experimental protocol
| Group I (Control)
Water for injection was administered 40 minutes before isolating heart, and then, heart was isolated and perfused on Langendorff's apparatus. After mounting, the heart was allowed to stabilize for 10 minutes and then subjected to 30 minutes global ischemia and 120 minutes of reperfusion.
| Group II (Adenosine preconditioning)
Adenosine (4 mg/kg ip) was administered and after 40 minutes, heart was isolated and was subjected to ischemia and reperfusion as described in group I.
| Group III (SNP preconditioning)
SNP(5 mg/kg ip) was administered and after 40 minutes, heart was subjected to ischemia and reperfusion as described in group I.
| Group IV (Adenosine + L-NAME)
L-NAME (5 mg/kg ip) was administered 30 minutes before administering adenosine. After 40 minutes of adenosine administration, heart was subjected to ischemia and reperfusion as described in group I.
| Group V (Sodium nitroprusside + Caffeine)
Caffeine (20 mg/kg ip) was administered 30 minutes before administering SNP. After 40 minutes of SNP administration, heart was subjected to ischemia and reperfusion as described in group I.
| Group VI (Adenosine + Seratrodast)
Seratrodast (15 mg/kg ip) was administered 30 minutes before administering adenosine. After 40 minutes of adenosine administration, heart was subjected to ischemia and reperfusion as described in group I.
| Group VII (Adenosine + Montelukast)
Montelukast (10 mg/kg ip) was administered 30 minutes before administering adenosine. After 40 minutes of adenosine administration, heart was subjected to ischemia and reperfusion as described in group I.
| Group VIII (SNP + Seratrodast)
Seratrodast (15 mg/kg ip) was administered 30 minutes before administering SNP. After 40 minutes of SNP administration, heart was subjected to ischemia and reperfusion as described in group I.
| Group IX (SNP + Montelukast)
Montelukast (10 mg/kg ip) was administered 30 minutes before administering SNP. After 40 minutes of SNP administration, heart was subjected to ischemia and reperfusion as described in group I.
| Group X (SNP + L-NAME)
L-NAME (5 mg/kg ip) was administered 30 minutes before administering SNP. After 40 minutes of SNP administration, heart was subjected to ischemia and reperfusion as described in group I.
| Group XI (Adenosine + Caffeine)
Caffeine (20 mg/kg ip) was administered 30 minutes before administering adenosine. After 40 minutes of adenosine administration, heart was subjected to ischemia and reperfusion as described in group I.
| Statistical analysis
All results were expressed as mean ± standard deviation (SD). The statistical analysis for LDH, CK, LVDP, +dp/dtmax, and −dp/dt min was done using two-way repeated measure ANOVA followed by Bonferonni's post hoc test. The infarct size was analyzed using oneway ANOVA followed by Tukey's post hoc test. The outcome value of p < .05 was considered to be statistically significant.
| RE SULTS
| Effect of different pharmacological interventions on infarct size
Thirty minutes of global ischemia and 120 minutes of reperfusion significantly produced myocardial infarction, measured by volume and weight methods. However, pharmacological preconditioning with adenosine and SNP elicited the infarct-sparing effects.
Moreover, pretreatment with L-NAME (5 mg/kg ip), montelukast L-NAME (5 mg/kg ip) had no effect on infarct sparring effect of SNP (Figure 1 ).
| Effect of different pharmacological interventions on LDH and ck release
Thirty minutes of global ischemia and 120 minutes of reperfusion significantly increased the LDH and CK release from the myocardium to the coronary effluent. The peak release of LDH was recorded immediately after reperfusion and at 30 minutes of reperfusion, while peak release of CK occurred at 5 minutes of reperfusion. Preconditioning with adenosine and SNP significantly reduced ischemia-reperfusion-induced increase in LDH and CK release. Moreover, pretreatment with L-NAME, montelukast, and caffeine before adenosine preconditioning significantly abrogated adenosine-induced decrease in LDH and CK release. On the other hand, seratrodast had no effect on adenosine-induced decrease in LDH and CK release. Pretreatment with montelukast before SNP treatment abrogated SNP-induced decrease in biochemical parameters, whereas caffeine, seratrodast, and L-NAME had no effect on SNP-induced decrease in LDH and CK release (Figures 2 and 3 ).
| Effect of different pharmacological
interventions on LVDP, +dp/dt max and −dp/dt min Thirty minutes of global ischemia resulted in significant decrease in LVDP, +dp/dt max, and −dp/dt min during reperfusion period. Adenosine and SNP preconditioning significantly attenuated ischemia-reperfusion-induced decrease in LVDP, +dp/dt max, and − dp/dt min during reperfusion. Moreover, pretreatment with L-NAME, montelukast, and caffeine significantly abrogated adenosineinduced improvement in LVDP, +dp/dt max, and −dp/dt min . Seratrodast had no effect on adenosine-induced improvement in contractility parameters during reperfusion. Pretreatment with montelukast also abrogated SNP-induced improvement in LVDP, +dp/dt max, and −dp/ dt min . Caffeine, seratrodast, and L-NAME had no effect on SNPinduced improvement in contractility parameters (Tables 1,2,3) .
| Effect of different pharmacological interventions on serum nitrite levels
Adenosine and SNP preconditioning significantly increased the serum nitrite levels, measured immediately before isolating heart.
However, pretreatment with L-NAME and caffeine significantly abrogated adenosine-induced increase in serum nitrite levels.
Pretreatment with caffeine and L-NAME had no effect on SNPinduced increase in serum nitrite levels. Pretreatment with montelukast and seratrodast did not modulate adenosine and SNP-induced increase in serum nitrite levels ( Figure 4 ).
| D ISCUSS I ON
In the present study, 30 minutes of global ischemia followed by 120 minutes of reperfusion produced an increase in myocardial infarct size, LDH and CK release in coronary effluent, and decrease in LVDP, +dp/dt max , −dp/dt min . LDH and CK are the cardiac enzymes, which are released during ischemia-reperfusion injury. 30 Our previous studies had reported that peak release of LDH occurs immediately after reperfusion and at 30 minutes of reperfusion, while the peak release of CK occurs at 5 minutes of reperfusion. 31 Ischemia-reperfusion-induced extent of myocardial injury including myocardial infarction is in consonance with previous reports from our laboratory 32, 33 as well as from other laboratories.
34,35
In the present study, administration of adenosine in rats (in the form of adenosine preconditioning) significantly attenuated ischemia-reperfusion-induced injury. There have been studies
showing the cardioprotective effects of adenosine preconditioning. 23, 36 Intravenous administration of adenosine may produce a number of side effects including flushing, dyspnea, and hypotension. However, intraperitoneal administration of adenosine is not associated with fall in blood pressure or hypotension. 37 In the present study, also, adenosine was tolerated, and no visible signs of adverse effects were observed. Adenosine preconditioning also led to significant increase in the serum nitrite levels, assessed 40 minutes after its administration at the time of isolation of heart. Serum nitrite level reflects the nitric oxide levels and an increase or decrease in serum nitrite levels indicates an increase or decrease in nitric oxide level. 38 Pretreatment with caffeine, a nonselective adenosine receptor antagonist, 39 significantly attenuated adenosine mediated cardioprotection along with rise in serum nitrite levels.
These results suggest that adenosine may increase the nitric oxide production to confer cardioprotection. Nitric oxide is an important endogenous molecule and its role in preconditioning has been well documented. 40 Our present study results also demonstrated that administration of SNP in the form of preconditioning stimulus also abolished ischemia-reperfusion-induced injury and conferred cardioprotection. SNP is a nitric oxide donor and is widely used for this purpose. 41, 42 In the present study, pretreatment with L-NAME, a specific NOS inhibitor, 43 abolished adenosine preconditioninginduced cardioprotective effects. There have been earlier studies showing that adenosine increases the nitric oxide production from vascular endothelial cells. [44] [45] [46] Therefore, it may be proposed that adenosine preconditioning-induced cardioprotective effects may be linked to increase in nitric oxide production. However, pretreatment with L-NAME neither modulated SNP-induced cardioprotection nor increase in nitrite levels. As, L-NAME is NO synthesis inhibitor; therefore, it may not abolish the cardioprotective effects of NO due to its exogenous administration in the form SNP preconditioning.
To explore whether nitric oxide-induced cardioprotection in the form of preconditioning is mediated through adenosine, caffeine was administered in SNP preconditioning group. However, pretreatment with caffeine did not modulate SNP-induced preconditioning effect suggesting that NO does not produce cardioprotection through adenosine. In other words, it may be stated that nitric oxide is the downstream target of adenosine preconditioning.
Our previous finding elucidated the key role of cysLTs and TXA 2 in RIPC-induced cardioprotection. 16, 22 TXA 2 is an arachidonic acid The data were statistically analyzed using two-way ANOVA followed by Bonefferoni test. The data were statistically analyzed using two-way ANOVA followed by Bonefferoni test. All values of dp/dt max were in mm Hg/s. Values were expressed as mean ± SD with n = 6. For treatment, F (10, 275) = 466. 12 There have been earlier studies showing that adenosine and nitric oxide may increase the levels of cysLTs.
48,49
However, in the present study, administration of seratrodast neither modulated adenosine and SNP preconditioning-induced cardioprotection nor serum nitrite levels, suggesting that TXA 2 may not participate in adenosine and SNP-induced cardioprotection.
| CON CLUS ION
Adenosine preconditioning-induced cardioprotection from ischemiareperfusion injury may be mediated through increased release of nitric oxide, which in turn may increase cysteinyl leukotrienes to confer cardioprotection. There may be no role of thromboxane A 2 in adenosine preconditioning-induced cardioprotective effect.
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